Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Xeomin® (incobotulinumtoxinA) – New indication
July 3, 2018 - Merz North America announced the FDA approval of Xeomin (incobotulinumtoxinA), for the treatment of chronic sialorrhea in adult patients.
